

Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

<https://marketpublishers.com/r/P7A61693A18EN.html>

Date: March 2018

Pages: 118

Price: US\$ 1,235.00 (Single User License)

ID: P7A61693A18EN

Abstracts

Pulmonary Arterial Hypertension (PAH) is a rare and catastrophic condition, with an estimated market value of over \$4 billion. The chronic and rapidly progressing disease affects around 0.2 million to 0.3 million people globally.

It is characterized by enlargement of arterial walls within the small pulmonary arteries transporting high pressure blood between the heart and lungs, resulting in strain on the heart and thereby, restricted blood flow. Disease symptoms include breath shortage, chest pain and fainting episodes.

Endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogues and soluble guanylate cyclase (sGC) stimulators are the primary treatment options for PAH. However, as the underlying mechanism is yet unknown, the current therapies reduce the effect of PAH but do not impact the underlying cause.

The most comprehensive pipeline review “Pulmonary Arterial Hypertension (PAH)- Drug Development Pipeline Study” provides in-depth analysis and update information on Pulmonary Arterial Hypertension (PAH) pipeline drugs. Current status of all the drugs in the Pulmonary Arterial Hypertension (PAH) pipeline is provided in the research work.

The report provides detailed analysis of Pulmonary Arterial Hypertension (PAH) pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World)). Further, the Pulmonary Arterial Hypertension (PAH) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Pulmonary Arterial Hypertension (PAH) industry.

Scope:

- All latest industry developments and their impact on projects and companies
- Complete overview of global Pulmonary Arterial Hypertension (PAH) therapy options and treatments
- The pipeline study reviews drug details for Pulmonary Arterial Hypertension (PAH) by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Pulmonary Arterial Hypertension (PAH) market
- Pulmonary Arterial Hypertension (PAH) drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed with their current status, partners and news updates

Contents

1 TABLE OF CONTENTS

1.1 LIST OF FIGURES

1.2 LIST OF TABLES

2 EXECUTIVE SUMMARY

2.1 DISEASE OVERVIEW

2.2 PIPELINE SNAPSHOT

2.3 PIPELINE DRUGS BY PHASE

2.4 PIPELINE DRUGS BY COMPANY

2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

3 PULMONARY ARTERIAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS

3.1 AADI BIOSCIENCE, INC. PIPELINE, H1 2018

3.2 Acceleron Pharma Inc PIPELINE, H1 2018

3.3 ACTELION PHARMACEUTICALS PIPELINE, H1 2018

3.4 Aerogen Pharma Limited PIPELINE, H1 2018

3.5 APT Therapeutics, Inc. PIPELINE, H1 2018

3.6 Arena Pharmaceuticals Inc.PIPELINE, H1 2018

3.7 ASKLEPION PHARMACEUTICALS, LLCPIPELINE, H1 2018

3.8 AVEO PHARMACEUTICALS INC. PIPELINE, H1 2018

3.9 BIAL-PORTELA & CA. S.A PIPELINE, H1 2018

3.10 BIOGEN, INC. PIPELINE, H1 2018

3.11 BRISTOL-MYERS SQUIBB CO PIPELINE, H1 2018

3.12 Camurus AB PIPELINE, H1 2018

3.13 CAPRICOR THERAPEUTICS, INC PIPELINE, H1 2018

3.14 CELSION CORP PIPELINE, H1 2018

3.15 CELTAXSYS, INC. PIPELINE, H1 2018

3.16 CHUGAI PHARMACEUTICAL CO LTD PIPELINE, H1 2018

3.17 Complexa Inc PIPELINE, H1 2018

3.18 CORSAIR PHARMA, INC. PIPELINE, H1 2018

3.19 GALECTIN THERAPEUTICS INC PIPELINE, H1 2018

3.20 GLAXOSMITHKLINE PHARMACEUTICALS LTDPIPELINE, H1 2018

3.21 GMAX BIOPHARM BIOMEDICAL ENGINEERING CO., LTD.PIPELINE, H1 2018

- 3.22 INSMED, INC.PIPELINE, H1 2018
- 3.23 INVENT PHARMACEUTICALS, INC. PIPELINE, H1 2018
- 3.24 KAROS PHARMACEUTICALS, INC PIPELINE, H1 2018
- 3.25 LIQUIDIA TECHNOLOGIES INC PIPELINE, H1 2018
- 3.26 LTT BIO-PHARMA CO., LTD. PIPELINE, H1 2018
- 3.27 LUNG BIOTECHNOLOGY PBC PIPELINE, H1 2018
- 3.28 MANKIND CORP PIPELINE, H1 2018
- 3.29 MaxCyte, Inc. PIPELINE, H1 2018
- 3.30 MEZZION PHARMA CO LTD PIPELINE, H1 2018
- 3.31 MIFCARE.CA PIPELINE, H1 2018
- 3.32 MORPHOGEN-IX LIMITED PIPELINE, H1 2018
- 3.33 NOVARTIS INTERNATIONAL AG PIPELINE, H1 2018
- 3.34 PELOTON THERAPEUTICS INC PIPELINE, H1 2018
- 3.35 PHASEBIO PHARMACEUTICALS, INC PIPELINE, H1 2018
- 3.36 PROTEO BIOTECH AG PIPELINE, H1 2018
- 3.37 PULMOKINE, INC PIPELINE, H1 2018
- 3.38 RADIKAL THERAPEUTICS INC PIPELINE, H1 2018
- 3.39 Reata Pharmaceuticals Inc PIPELINE, H1 2018
- 3.40 RESPIRA THERAPEUTICS, INC PIPELINE, H1 2018
- 3.41 Reviva Pharmaceuticals, Inc PIPELINE, H1 2018
- 3.42 SAVARA INC PIPELINE, H1 2018
- 3.43 Selten Pharma, LLC. PIPELINE, H1 2018
- 3.44 SERODUS ASA PIPELINE, H1 2018
- 3.45 STEADYMED THERAPEUTICS INC PIPELINE, H1 2018
- 3.46 SUDA LTD PIPELINE, H1 2018
- 3.47 Tritech Biopharmaceuticals Co Ltd PIPELINE, H1 2018
- 3.48 Vicore Pharma AB PIPELINE, H1 2018
- 3.49 Vivus Inc PIPELINE, H1 2018

4 PULMONARY ARTERIAL HYPERTENSION DRUG SNAPSHOTS

4.1 SOTATERCEPT DRUG DETAILS

- 4.1.1 Snapshot-
- 4.1.2 Drug Details
- 4.1.3 Mechanism of Action
- 4.1.4 Current Status

4.2 Epoprostenol inhalation (floan) Drug Details

- 4.2.1 Snapshot-
- 4.2.2 Drug Overview

- 4.2.3 Mechanism of Action
- 4.2.4 Current Status
- 4.2.5 Trial details
- 4.3 Ralinepag Drug Details
 - 4.3.1 Snapshot-
 - 4.3.2 Drug Overview
 - 4.3.3 Mechanism of Action
 - 4.3.4 Current Status
 - 4.3.5 Trial details
- 4.4 Beraprost 314d Drug Details
 - 4.4.1 Snapshot-
 - 4.4.2 Drug Overview
 - 4.4.3 Mechanism of Action
 - 4.4.4 Current Status
 - 4.4.5 Trial details
- 4.5 LT-2004 Drug Details
 - 4.5.1 Snapshot-
 - 4.5.2 Drug overview
 - 4.5.3 Mechanism of Action
 - 4.5.4 Current Status
- 4.6 Intravenous L-citrulline Drug Details
 - 4.6.1 Snapshot-
 - 4.6.2 Drug Overview
 - 4.6.3 Mechanism of Action
 - 4.6.4 Current Status
- 4.7 AV-353 Drug Details
 - 4.7.1 Snapshot-
 - 4.7.2 Drug Overview
 - 4.7.3 Mechanism of Action
 - 4.7.4 Current Status
 - 4.7.5 Trial details
- 4.8 BIA 5-1058 Drug Details
 - 4.8.1 Snapshot-
 - 4.8.2 Drug Overview
 - 4.8.3 Mechanism of Action
 - 4.8.4 Current Status
 - 4.8.5 Trial details
- 4.9 Dimethyl Fumarate Drug Details
 - 4.9.1 Snapshot-

- 4.9.2 Drug Overview
- 4.9.3 Mechanism of Action
- 4.9.4 Current Status
- 4.9.5 Trial details
- 4.10 CXL-1036 Drug Details
 - 4.10.1 Snapshot-
 - 4.10.2 Drug Overview
 - 4.10.3 Mechanism of Action
 - 4.10.4 Current Status
- 4.11 CAM 2043 Drug Details
 - 4.11.1 Snapshot-
 - 4.11.2 Drug Overview
 - 4.11.3 Mechanism of Action
 - 4.11.4 Current Status
 - 4.11.5 Trial Details
- 4.12 CAP 1002 Drug Details
 - 4.12.1 Snapshot-
 - 4.12.2 Drug Overview
 - 4.12.3 Mechanism of Action
 - 4.12.4 Current Status
 - 4.12.5 Trial details
- 4.13 TheraSilence Drug Details
 - 4.13.1 Snapshot-
 - 4.13.2 Drug Overview
 - 4.13.3 Mechanism of Action
 - 4.13.4 Current Status
 - 4.13.5 Trial Details
- 4.14 acebilustat Drug Details
 - 4.14.1 Snapshot-
 - 4.14.2 Drug Overview
 - 4.14.3 Mechanism of Action
 - 4.14.4 Current Status
- 4.15 tocilizumab Drug Details
 - 4.15.1 Snapshot-
 - 4.15.2 Drug Overview
 - 4.15.3 Mechanism of Action
 - 4.15.4 Current Status
 - 4.15.5 Trial details
- 4.16 CXA-10 Drug Details

- 4.16.1 Snapshot-
- 4.16.2 Drug Overview
- 4.16.3 Mechanism of Action
- 4.16.4 Current Status
- 4.16.5 Trial details
- 4.17 GM CT-01 Drug Details
 - 4.17.1 Snapshot-
 - 4.17.2 Drug Overview
 - 4.17.3 Mechanism of Action
 - 4.17.4 Current Status
 - 4.17.5 Trial Details
- 4.18 GR MD-02 Drug Details
 - 4.18.1 Snapshot-
 - 4.18.2 Drug Overview
 - 4.18.3 Mechanism of Action
 - 4.18.4 Current Status
 - 4.18.5 Trial Details
- 4.19 GSK 2256098 Drug Details
 - 4.19.1 Snapshot-
 - 4.19.2 Drug Overview
 - 4.19.3 Mechanism of Action
 - 4.19.4 Current Status
 - 4.19.5 Trial Details
- 4.20 GSK 2586881 Drug Details
 - 4.20.1 Snapshot-
 - 4.20.2 Drug Overview
 - 4.20.3 Mechanism of Action
 - 4.20.4 Current Status
 - 4.20.5 Trial details
- 4.21 INS1009 Drug Details
 - 4.21.1 Snapshot-
 - 4.21.2 Drug Overview
 - 4.21.3 Mechanism of Action
 - 4.21.4 Current Status
 - 4.21.5 Trial details
- 4.22 LIQ861 Drug Details
 - 4.22.1 Snapshot-
 - 4.22.2 Drug Overview
 - 4.22.3 Mechanism of Action

- 4.22.4 Current Status
- 4.22.5 Trial Details
- 4.23 Treprostinil Technosphere Drug Details
 - 4.23.1 Snapshot-
 - 4.23.2 Drug Overview
 - 4.23.3 Mechanism of Action
 - 4.23.4 Current Status
- 4.24 Udenafil Drug Details
 - 4.24.1 Snapshot-
 - 4.24.2 Drug Overview
 - 4.24.3 Mechanism of Action
 - 4.24.4 Current Status
 - 4.24.5 Trial details
- 4.25 eNOS-EPC Cells Drug Details
 - 4.25.1 Snapshot-
 - 4.25.2 Drug Overview
 - 4.25.3 Mechanism of Action
 - 4.25.4 Current Status
 - 4.25.5 Trial Details
- 4.26 QCC 374 Drug Details
 - 4.26.1 Snapshot-
 - 4.26.2 Drug Overview
 - 4.26.3 Mechanism of Action
 - 4.26.4 Current Status
 - 4.26.5 Trial details
- 4.27 PT2567 Drug Details
 - 4.27.1 Snapshot-
 - 4.27.2 Drug Overview
 - 4.27.3 Mechanism of Action
 - 4.27.4 Current Status
- 4.28 PB1046 Drug Details
 - 4.28.1 Snapshot-
 - 4.28.2 Drug Overview
 - 4.28.3 Mechanism of Action
 - 4.28.4 Current Status
 - 4.28.5 Trial Details
- 4.29 PK10571 Drug Details
 - 4.29.1 Snapshot-
 - 4.29.2 Drug Overview

- 4.29.3 Mechanism of Action
- 4.29.4 Current Status
- 4.30 Bardoxolone Methyl Drug Details
 - 4.30.1 Snapshot-
 - 4.30.2 Drug Overview
 - 4.30.3 Mechanism of Action
 - 4.30.4 Current Status
 - 4.30.5 Trial Details
- 4.31 RT234 AOS DPI Drug Details
 - 4.31.1 Snapshot-
 - 4.31.2 Drug Overview
 - 4.31.3 Mechanism of Action
 - 4.31.4 Current Status
- 4.32 RP5063 Drug Details
 - 4.32.1 Snapshot-
 - 4.32.2 Drug Overview
 - 4.32.3 Mechanism of Action
 - 4.32.4 Current Status
 - 4.32.5 Trial details
- 4.33 Aironite Drug Details
 - 4.33.1 Snapshot-
 - 4.33.2 Drug Overview
 - 4.33.3 Mechanism of Action
 - 4.33.4 Current Status
 - 4.33.5 Trial Details
- 4.34 SER100PH Drug Details
 - 4.34.1 Snapshot-
 - 4.34.2 Drug Overview
 - 4.34.3 Mechanism of Action
 - 4.34.4 Current Status
- 4.35 Treprostinil Patch Pump Drug Details
 - 4.35.1 Snapshot-
 - 4.35.2 Drug Overview
 - 4.35.3 Mechanism of Action
 - 4.35.4 Current Status
- 4.36 SUD-004 Drug Details
 - 4.36.1 Snapshot-
 - 4.36.2 Drug Overview
 - 4.36.3 Current Status

- 4.36.4 Mechanism of Action
- 4.37 treprostinil prodrug transdermal Drug Details
 - 4.37.1 Snapshot-
 - 4.37.2 Drug Overview
 - 4.37.3 Mechanism of Action
 - 4.37.4 Current Status
- 4.38 C21 Drug Details
 - 4.38.1 Snapshot-
 - 4.38.2 Drug Overview
 - 4.38.3 Mechanism of Action
 - 4.38.4 Current Status
 - 4.38.5 Trial Details
- 4.39 Macitentan/tadalafil Drug Details
 - 4.39.1 Snapshot-
 - 4.39.2 Drug Overview
 - 4.39.3 Mechanism of Action
 - 4.39.4 Current Status
 - 4.39.5 Trial details
- 4.40 APT-102 Drug Details
 - 4.40.1 Snapshot-
 - 4.40.2 Drug Overview
 - 4.40.3 Mechanism of Action
 - 4.40.4 Current Status
 - 4.40.5 Trial Details
- 4.41 BMP10 Drug Details
 - 4.41.1 Snapshot-
 - 4.41.2 Drug Overview
 - 4.41.3 Mechanism of Action
 - 4.41.4 Current Status
- 4.42 BMP9 Drug Details
 - 4.42.1 Snapshot-
 - 4.42.2 Drug Overview
 - 4.42.3 Mechanism of Action
 - 4.42.4 Current Status
 - 4.42.5 Trial details
- 4.43 GMA302 Drug Details
 - 4.43.1 Snapshot-
 - 4.43.2 Drug Overview
 - 4.43.3 Mechanism of Action

- 4.43.4 Current Status
- 4.43.5 Trial Details
- 4.44 INV-240 Drug Details
 - 4.44.1 Snapshot-
 - 4.44.2 Drug Overview
 - 4.44.3 Mechanism of Action
 - 4.44.4 Current Status
- 4.45 KAR5585 Drug Details
 - 4.45.1 Snapshot-
 - 4.45.2 Drug Overview
 - 4.45.3 Mechanism of Action
 - 4.45.4 Current Status
 - 4.45.5 Trial Details
- 4.46 MFC1040 Drug Details
 - 4.46.1 Snapshot-
 - 4.46.2 Drug Overview
 - 4.46.3 Mechanism of Action
 - 4.46.4 Current Status
 - 4.46.5 Trial Details
- 4.47 MFC2040 Drug Details
 - 4.47.1 Snapshot-
 - 4.47.2 Drug Overview
 - 4.47.3 Mechanism of Action
 - 4.47.4 Current Status
- 4.48 R197 Drug Details
 - 4.48.1 Snapshot-
 - 4.48.2 Drug Overview
 - 4.48.3 Mechanism of Action
 - 4.48.4 Current Status
- 4.49 ABI-009 Drug Details
 - 4.49.1 Snapshot-
 - 4.49.2 Drug Overview
 - 4.49.3 Mechanism of Action
 - 4.49.4 Current Status
- 4.50 SPI-054 Drug Details
 - 4.50.1 Snapshot-
 - 4.50.2 Drug Overview
 - 4.50.3 Mechanism of Action
 - 4.50.4 Current Status

- 4.50.5 Trial Details
- 4.51 Tacrolimus Drug Details
 - 4.51.1 Snapshot-
 - 4.51.2 Drug Overview
 - 4.51.3 Mechanism of Action
 - 4.51.4 Current Status
 - 4.51.5 Trial Details
- 4.52 Tiprelestat Drug Details
 - 4.52.1 Snapshot-
 - 4.52.2 Drug Overview
 - 4.52.3 Mechanism of Action
 - 4.52.4 Current Status
 - 4.52.5 Trial Details
- 4.53 TR-422 Drug Details
 - 4.53.1 Snapshot-
 - 4.53.2 Drug Overview
 - 4.53.3 Mechanism of Action
 - 4.53.4 Current Status

5 RECENT DEVELOPMENTS IN PULMONARY ARTERIAL HYPERTENSION PIPELINE

- 5.1 ACCELERON ANNOUNCES PRECLINICAL RESULTS IN PULMONARY ARTERIAL HYPERTENSION- NOVEMBER 2017
- 5.2 RALINEPAG SHOWS PROMISE IN TREATING PAH- OCTOBER 2017
- 5.3 CAPRICOR ANNOUNCES SEVEN NEW PATENT APPLICATIONS FROM CEDARS-SINAI MEDICAL CENTER- JANUARY 2018
- 5.4 FDA AGREES FOR RESUBMISSION OF TREVYENT NDA APPLICATION- DECEMBER 2017
- 5.5 CORSAIR PHARMA AND UNITED THERAPEUTICS FORM STRATEGIC PARTNERSHIP- JANUARY 2018

6 APPENDIX

- 6.1 ABOUT VPA RESEARCH
- 6.2 SOURCES AND RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure 1: Pulmonary Arterial Hypertension Pipeline by Phase, H1- 2018

Figure 2: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018

Figure 3: Company wise Pipeline Drug Phases, H1- 2018

Figure 4: Pulmonary Arterial Hypertension Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Pulmonary Arterial Hypertension Pipeline by Phase, H1- 2018
- Table 2: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018 (1)
- Table 3: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018 (2)
- Table 4: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018 (3)
- Table 5: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018 (4)
- Table 6: Pulmonary Arterial Hypertension Pipeline by Companies, H1- 2018 (5)
- Table 7: Pulmonary Arterial Hypertension Pipeline by Mechanism of Action, H1- 2018
- Table 8: Aadi Bioscience, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 9: Acceleron Pharma Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 10: Actelion Pharmaceuticals- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 11: Aerogen Pharma Limited- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 12: APT Therapeutics, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 13: Arena Pharmaceuticals Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 14: Asklepiion Pharmaceuticals, LLC- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 15: AVEO Pharmaceuticals Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 16: Bial-Portela & Ca. S.A- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 17: Biogen, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 18: Bristol-Myers Squibb Co- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 19: Camurus AB- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 20: Capricor Therapeutics, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 21: Celsion Corp- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 22: Celtaxsys, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 23: Chugai Pharmaceutical Co Ltd- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 24: Complexa Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 25: Corsair Pharma, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 26: Galectin Therapeutics Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018
- Table 27: GlaxoSmithKline Pharmaceuticals Ltd- Pulmonary Arterial Hypertension

Pipeline, H1- 2018

Table 28: Gmax Biopharm Biomedical Engineering Co., Ltd.- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 29: Insmad, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 30: Invent Pharmaceuticals, Inc. - Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 31: Karos Pharmaceuticals, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 32: Liquidia Technologies Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 33: LTT Bio-Pharma Co., Ltd.- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 34: Lung Biotechnology PBC- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 35: MannKind Corp- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 36: MaxCyte, Inc.- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 37: Mezzion Pharma Co Ltd- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 38: Mifcare.ca- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 39: MORPHOGEN-IX Limited- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 40: Novartis International AG- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 41: Peloton Therapeutics Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 42: PhaseBio Pharmaceuticals, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 43: Proteo Biotech AG- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 44: Pulmokine, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 45: Radikal Therapeutics Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 46: Reata Pharmaceuticals Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 47: Respira Therapeutics, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 48: Reviva Pharmaceuticals, Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 49: Savara Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 50: Selten Pharma, LLC.- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 51: Serodus ASA- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 52: SteadyMed Therapeutics Inc- Pulmonary Arterial Hypertension Pipeline, H1-

2018

Table 53: Suda Ltd- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 54: Tritech Biopharmaceuticals Co Ltd- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 55: Vicore Pharma AB- Pulmonary Arterial Hypertension Pipeline, H1- 2018

Table 56: Vivus Inc- Pulmonary Arterial Hypertension Pipeline, H1- 2018

I would like to order

Product name: Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

Product link: <https://marketpublishers.com/r/P7A61693A18EN.html>

Price: US\$ 1,235.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7A61693A18EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970